MTOB (sodium salt)

MTOB is an intermediate in the methionine salvage pathway.¹ It is also a substrate of the dehydrogenase domain of C-terminal-binding protein 1 (CtBP1) and CtBP2 that inhibits the transcriptional corepressor activity of CtBP1 and -2 at concentrations in the millimolar range.² MTOB reduces cell viability in p53 wild-type and p53 knockout HCT116 colorectal cancer cells and induces apoptosis in p53 knockout HCT116 cells. It inhibits growth of MCF-7 breast cancer, MDA-MB-231 breast cancer, and U2OS osteosarcoma cells in a concentration-dependent manner. MTOB reduces tumor mass and ascites volume in a mouse xenograft model using HCT116 cells lacking p53 when administered at a dose of 750 mg/kg. It also reduces the neurological severity score (NSS) and the loss of righting reflex duration in a mouse model of traumatic brain injury.³

WARNING This product is not for human or veterinary use.

1. Subhi, A.L., Diegelman, P., Porter, C.W., et al. Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. The Journal of Biological Chemisty 278(50), 49868-49873 (2003).

2. Straza, M.W., Paliwal, S., Kovi, R.C., et al. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle 9(18), 3740-3750 (2010).

3. Li, H., Zhang, C., Yang, C., et al. C-terminal binding proteins 1 and 2 in traumatic brain injury-induced inflammation and their inhibition as an approach for anti-inflammatory treatment. Int. J. Biol. Sci. 16(7), 1107-1120 (2020).